Teprotumumab N01

替妥尤单抗 N01

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTeprotumumab N01
Drug Alias NameTeprotumumab biosimilar (Innovent)替妥尤单抗生物类似药 (信达生物)信必敏SYCUMEIBI-311
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsGraves OphthalmopathyOptic Nerve Diseases
Global Approved IndicationsGraves Ophthalmopathy
Approved Indications in ChinaGraves Ophthalmopathy
Original Approved Country/TerritoryMainland China
Original Approved Date2025/03/11
Country/TerritoryMacauMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSun Yat-Sen UniversityInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsGraves OphthalmopathyOptic Nerve Diseases
Inactive IndicationsN/A

Other Information

ATC CodeL01XC
Related LinksN/A